Associate Professor Luke Selth is a Cancer Council SA Beat Cancer Principal Cancer Research Fellow in the Flinders Health and Medical Research Institute (FHMRI) at Flinders University, where he leads the Prostate Cancer Research Group. He is a member of the Freemasons Centre for Male Health and Wellbeing (FCMHW) and sits on the Scientific Advisory Committee for the South Australian Genomics Centre.
A/Prof Selth has established an internationally-recognised research program focused on understanding and targeting androgen receptor signalling in prostate cancer, investigating prostate cancer cell plasticity and how it leads to therapy resistance, and testing the efficacy of novel drugs for prostate cancer.
A/Prof Selth did a Biotechnology degree at Flinders University, a PhD at University of Adelaide and then post-doctoral studies at Cancer Research UK’s London Research Institute. As a recipient of a prestigious European Molecular Biology Organization long-term fellowship, Selth studied epigenetic mechanisms underlying transcriptional deregulation in cancer and developed expertise in contemporary molecular, biochemical and omic techniques. Since returning to Australia, Selth’s research has been focussed on prostate cancer, an extremely common disease and a major cause of cancer-related death in men.
Selth has been received Young Investigator Awards from the Prostate Cancer Foundation of Australia (PCFA) and the Prostate Cancer Foundation, the latter one of only two awarded to an Australian-based researcher (of >300 total since 2007), as well as funding from the National Health and Medical Research Council, Cancer Australia, Movember and The Hospital Research Foundation. His team’s research is regularly published in prominent journals including recent papers in Cancer Research, European Urology, Science Translational Medicine, Nature Medicine, EMBO Journal, Oncogene, and Nucleic Acids Research.
Google Scholar: https://scholar.google.com.au/citations?user=IfXWSaQAAAAJ&hl=en
You consent to the use of our cookies if you proceed.